Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

In utero exposure to ADHD medication and long-term offspring outcomes

Molecular Psychiatry volume 28, pages 1739–1746 (2023)Cite this article

Subjects

Abstract

Attention Deficit Hyperactivity Disorder (ADHD) medication is increasingly being used during pregnancy. Concerns have been raised as to whether ADHD medication has long-term adverse effects on the offspring. The authors investigated whether in utero exposure to ADHD medication was associated with adverse long-term neurodevelopmental and growth outcomes in offspring. The population-based cohort study in the Danish national registers included 1,068,073 liveborn singletons from 1998 to 2015 followed until any developmental diagnosis, death, emigration, or December 31, 2018. Children of mothers who continued ADHD medication (methylphenidate, amphetamine, dexamphetamine, lisdexamphetamine, modafinil, atomoxetine, clonidine) during pregnancy and children of mothers who discontinued ADHD medication before pregnancy were compared using Cox regression. Main outcomes were neurodevelopmental psychiatric disorders, impairments in vision or hearing, epilepsy, seizures, or growth impairment during childhood or adolescence. In total, 898 children were exposed to ADHD medication during pregnancy compared to 1270 children whose mothers discontinued ADHD medication before pregnancy. After adjustment for demographic and psychiatric characteristics of the mother, no increased risk of any offspring developmental disorders was found combined (aHR 0.97, 95% CI 0.81 to 1.17) or for separate subcategories. Similarly, no increased risk was found for any sub-categories of outcomes in the negative control or sibling controlled analyses. Neurodevelopment and growth in offspring do not differ based on antenatal exposure to ADHD medication. These findings provide reassurance for women with ADHD who depend on ADHD medication for daily functioning and who consider continuing medication in pregnancy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1

Similar content being viewed by others

Code availability

Statistical analyses were performed in Stata 15.1 (StataCorp, College Station, TX, USA) and code to perform analyses can be made available by request.

References

  1. Franke B, Michelini G, Asherson P, Banaschewski T, Bilbow A, Buitelaar JK, et al. Live fast, die young? A review on the developmental trajectories of ADHD across the lifespan. Eur Neuropsychopharmacol. 2018;28:1059–88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Zetterqvist J, Asherson P, Halldner L, Långström N, Larsson H. Stimulant and non-stimulant attention deficit/hyperactivity disorder drug use: total population study of trends and discontinuation patterns 2006-2009. Acta Psychiatr Scand. 2013;128:70–7.

    Article  CAS  PubMed  Google Scholar 

  3. Anderson KN, Ailes EC, Danielson M, Lind JN, Farr SL, Broussard CS, et al. Attention-deficit/hyperactivity disorder medication prescription claims among privately insured women aged 15–44 years - United States, 2003–2015. Morb Mortal Wkly Rep. 2018;67:66–70.

    Article  Google Scholar 

  4. Haervig KB, Mortensen LH, Hansen AV, Strandberg-Larsen K. Use of ADHD medication during pregnancy from 1999 to 2010: a Danish register-based study. Pharmacoepidemiol Drug Saf. 2014;23:526–33.

    Article  CAS  PubMed  Google Scholar 

  5. Lemelin M, Boukhris T, Zhao J-P, Sheehy O, Bérard A. Prevalence and determinants of attention-deficit/hyperactivity disorder (ADHD) medication use during pregnancy: results from the Quebec Pregnancy/Children Cohort. Pharmacol Res Perspect. 2021;9:e00781.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Louik C, Kerr S, Kelley KE, Mitchell AA. Increasing use of ADHD medications in pregnancy. Pharmacoepidemiol Drug Saf. 2015;24:218–20.

    Article  PubMed  PubMed Central  Google Scholar 

  7. McAllister-Williams RH, Baldwin DS, Cantwell R, Easter A, Gilvarry E, Glover V, et al. British Association for Psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017. J Psychopharmacol. 2017;31:519–52.

    Article  PubMed  Google Scholar 

  8. Leong C, Raymond C, Château D, Dahl M, Alessi-Severini S, Falk J, et al. Psychotropic drug use before, during, and after Pregnancy: A Population-Based Study in a Canadian Cohort (2001-2013). Can J Psychiatry Rev. 2017;62:543–50.

    Article  Google Scholar 

  9. Shaw M, Hodgkins P, Caci H, Young S, Kahle J, Woods AG, et al. A systematic review and analysis of long-term outcomes in attention deficit hyperactivity disorder: effects of treatment and non-treatment. BMC Med. 2012;10:99.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Boland H, DiSalvo M, Fried R, Woodworth KY, Wilens T, Faraone SV, et al. A literature review and meta-analysis on the effects of ADHD medications on functional outcomes. J Psychiatr Res. 2020;123:21–30.

    Article  PubMed  Google Scholar 

  11. Damer EA, Edens MA, van der Loos MLM, van Esenkbrink J, Bunkers I, van Roon EN, et al. Fifteen years’ experience with methylphenidate for attention-deficit disorder during pregnancy: Effects on birth weight, Apgar score and congenital malformation rates. Gen Hosp Psychiatry. 2021;73:9–15.

    Article  CAS  PubMed  Google Scholar 

  12. Damkier P, Broe A. First-trimester pregnancy exposure to modafinil and risk of congenital malformations. JAMA. 2020;323:374–6.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Huybrechts KF, Bröms G, Christensen LB, Einarsdóttir K, Engeland A, Furu K, et al. Association between methylphenidate and amphetamine use in pregnancy and risk of congenital malformations: a cohort study from the International Pregnancy Safety Study Consortium. JAMA Psychiatry. 2018;75:167–75.

    Article  PubMed  Google Scholar 

  14. Nörby U, Winbladh B, Källén K. Perinatal outcomes after treatment with ADHD medication during pregnancy. Pediatrics. 2017;140:e20170747.

    Article  PubMed  Google Scholar 

  15. Diav-Citrin O, Shechtman S, Arnon J, Wajnberg R, Borisch C, Beck E, et al. Methylphenidate in pregnancy: a multicenter, prospective, comparative, observational study. J Clin Psychiatry. 2016;77:1176–81.

    Article  PubMed  Google Scholar 

  16. Bro SP, Kjaersgaard MI, Parner ET, Sørensen MJ, Olsen J, Bech BH, et al. Adverse pregnancy outcomes after exposure to methylphenidate or atomoxetine during pregnancy. Clin Epidemiol. 2015;7:139–47.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Pottegård A, Hallas J, Andersen JT, Løkkegaard EC, Dideriksen D, Aagaard L, et al. First-trimester exposure to methylphenidate: a population-based cohort study. J Clin Psychiatry. 2014;75:e88–93.

    Article  PubMed  Google Scholar 

  18. Anderson KN, Dutton AC, Broussard CS, Farr SL, Lind JN, Visser SN, et al. ADHD medication use during pregnancy and risk for selected birth defects: national birth defects prevention study, 1998-2011. J Atten Disord. 2020;24:479–89.

    Article  PubMed  Google Scholar 

  19. Poulton AS, Armstrong B, Nanan RK. Perinatal outcomes of women diagnosed with attention-deficit/hyperactivity disorder: an Australian population-based cohort study. CNS Drugs. 2018;32:377–86.

    Article  PubMed  Google Scholar 

  20. Cohen JM, Hernández-Díaz S, Bateman BT, Park Y, Desai RJ, Gray KJ, et al. Placental complications associated with psychostimulant use in pregnancy. Obstet Gynecol. 2017;130:1192–201.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Ornoy A. Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. Pharm Res. 2018;35:46–46.

    Article  PubMed  Google Scholar 

  22. Kittel-Schneider S, Quednow BB, Leutritz AL, McNeill RV, Reif A. Parental ADHD in pregnancy and the postpartum period - a systematic review. Neurosci Biobehav Rev. 2021;124:63–77.

    Article  CAS  PubMed  Google Scholar 

  23. Li L, Sujan AC, Butwicka A, Chang Z, Cortese S, Quinn P, et al. Associations of prescribed ADHD medication in pregnancy with pregnancy-related and offspring outcomes: a systematic review. CNS drugs. 2020;34:731–47.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Larsson H. Transparent and complete reporting of confounding in observational research. JCPP Adv. 2022;2:e12086.

    Article  Google Scholar 

  25. Faraone SV, Larsson H. Genetics of attention deficit hyperactivity disorder. Mol Psychiatry. 2019;24:562–75.

    Article  CAS  PubMed  Google Scholar 

  26. Thomas SA, Matsumoto AM, Palmiter RD. Noradrenaline is essential for mouse fetal development. Nature. 1995;374:643–6.

    Article  CAS  PubMed  Google Scholar 

  27. Portbury AL, Chandra R, Groelle M, McMillian MK, Elias A, Herlong JR, et al. Catecholamines act via a beta-adrenergic receptor to maintain fetal heart rate and survival. Am J Physiol Heart Circ Physiol. 2003;284:H2069–77.

    Article  CAS  PubMed  Google Scholar 

  28. Carucci S, Balia C, Gagliano A, Lampis A, Buitelaar JK, Danckaerts M, et al. Long-term methylphenidate exposure and growth in children and adolescents with ADHD. A systematic review and meta-analysis. Neurosci Biobehav Rev. 2021;120:509–25.

    Article  CAS  PubMed  Google Scholar 

  29. Bliddal M, Broe A, Pottegård A, Olsen J, Langhoff-Roos J. The Danish Medical Birth Register. Eur J Epidemiol. 2018;33:27–36.

    Article  PubMed  Google Scholar 

  30. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health. 2011;39:30–3.

    Article  PubMed  Google Scholar 

  31. Kildemoes HW, Sorensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health. 2011;39:38–41.

    Article  PubMed  Google Scholar 

  32. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public health. 2011;39:54–7.

    Article  PubMed  Google Scholar 

  33. Petersson F, Baadsgaard M, Thygesen LC. Danish registers on personal labour market affiliation. Scand J Public Health. 2011;39:95–8.

    Article  PubMed  Google Scholar 

  34. Royston P, White IR. Multiple Imputation by Chained Equations (MICE): implementation in Stata. J Stat Softw. 2011;45:1–20.

    Article  Google Scholar 

  35. Lawlor DA, Tilling K, Davey Smith G. Triangulation in aetiological epidemiology. Int J Epidemiol. 2016;45:1866–86.

    PubMed  Google Scholar 

  36. Petersen AH, Lange T. What is the causal interpretation of sibling comparison designs? Epidemiology. 2020;31:75–81.

    Article  PubMed  Google Scholar 

  37. Lemelin M, Sheehy O, Zhao JP, Bérard A. Maternal ADHD medication use during pregnancy and the risk of ADHD in children: importance of genetic predispositions and impact of using a sibling analysis. Eur Neuropsychopharmacol. 2021;44:66–78.

    Article  CAS  PubMed  Google Scholar 

  38. Bowyer JF, Peterson SL, Rountree RL, Tor-Agbidye J, Wang GJ. Neuronal degeneration in rat forebrain resulting from D-amphetamine-induced convulsions is dependent on seizure severity and age. Brain Res. 1998;809:77–90.

    Article  CAS  PubMed  Google Scholar 

  39. Hesselman S, Wikman A, Skoglund C, Kopp Kallner H, Skalkidou A, Sundström-Poromaa I, et al. Association of maternal attention deficit hyperactivity disorder and preterm birth: a cohort study. BJOG. 2020;127:1480–7.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

KBM and TMO receive funding from Sygeforsikring “danmark” (Journalnr. 2021-0139). This study was also funded by the National Institute of Mental Health (NIMH) (R01MH122869). JWD reports funding from the Independent Research Fund Denmark (1133-00026B). The funding agencies had no role in the design, data collection, analysis, interpretation, writing the manuscript, or the decision to submit the manuscript for publication. The corresponding author had full access to the data and had final responsibility for data integrity and data analysis.

Author information

Author notes

  1. These authors contributed equally: Trine Munk-Olsen, Veerle Bergink.

Authors and Affiliations

  1. NCRR - National Centre for Register-based Research, School of Business and Social Sciences, Aarhus University, Aarhus, Denmark

    Kathrine Bang Madsen, Xiaoqin Liu, Natalie Momen, Julie Werenberg Dreier & Trine Munk-Olsen

  2. Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

    Thalia K. Robakis, Jeffrey H. Newcorn & Veerle Bergink

  3. School of Medical Sciences, Örebro University, Örebro, Sweden

    Henrik Larsson

  4. Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

    Henrik Larsson

  5. Department of Clinical Medicine, University of Bergen, Bergen, Norway

    Julie Werenberg Dreier

  6. Hans Christian Andersen’s Children’s Hospital, Odense University Hospital, Odense, Denmark

    Helene Kildegaard

  7. Clinical Pharmacology, Pharmacy and Environmental Medicine, University of Southern Denmark, Odense, Denmark

    Helene Kildegaard

  8. Department of Otorhinolaryngology and Audiology, Zealand University Hospital, Universty of Copenhagen, Køge, Denmark

    Jane Bjerg Groth

  9. Department of Clinical Medicine, Aarhus University, Aarhus, Denmark

    Per Hove Thomsen

  10. Research Center at the Department for Child‐ and Adolescent Psychiatry, Aarhus University Hospital, Skejby, Denmark

    Per Hove Thomsen

  11. Research Unit of Psychiatry, Institute for Clinical Research, University of Southern Denmark, Odense, Denmark

    Trine Munk-Olsen

  12. Department of Psychiatry, Erasmus Medical Centre Rotterdam, Rotterdam, The Netherlands

    Veerle Bergink

Authors
  1. Kathrine Bang Madsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thalia K. Robakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaoqin Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natalie Momen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Henrik Larsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Julie Werenberg Dreier
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Helene Kildegaard
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Jane Bjerg Groth
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jeffrey H. Newcorn
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Per Hove Thomsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Trine Munk-Olsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Veerle Bergink
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

KBM, TKR, XL, NM, TMO, and VB designed the study. KBM, NM, and XL conducted the analysis and KBM wrote the first draft of the manuscript. TKR, XL, NM, HL, JWD, HK, JBG, JHN, PHT, TMO, and VB made significant contributions to the interpretation of the analysis and writing of the study. All authors have revised the article critically and all share responsibility for the content of the manuscript. All authors have approved the manuscript.

Corresponding author

Correspondence to Kathrine Bang Madsen.

Ethics declarations

Competing interests

HL reports receiving grants from Shire Pharmaceuticals; personal fees from and serving as a speaker for Medice, Shire/Takeda Pharmaceuticals, and Evolan Pharma AB; and sponsorship for a conference on attention-deficit/hyperactivity disorder from Shire/Takeda Pharmaceuticals and Evolan Pharma AB, all outside the submitted work. HL is editor-in-chief of JCPP Advances. JHN reports the following disclosures (all unrelated to this work): consultant/advisory board for Adlon Therapeutics, Arbor, Corium, Lumos, Medice, Myriad, NLS, OnDosis, Rhodes, and Supernus; research support from Adlon, Otsuka, Shire, Supernus; honoraria for disease state lectures from Otsuka and Takeda, and served as a consultant for the US National Football League. PHT has received speakers fees from MEDICE and Takeda within the last 3 years. All other authors have nothing to declare.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bang Madsen, K., Robakis, T.K., Liu, X. et al. In utero exposure to ADHD medication and long-term offspring outcomes. Mol Psychiatry 28, 1739–1746 (2023). https://doi.org/10.1038/s41380-023-01992-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41380-023-01992-6

This article is cited by

Search

Advanced search

Quick links